InSilico Medicine

OverviewSuggest Edit

Our mission statement and our pledge to our investors, friends and families: Through excellence in knowledge management, machine learning and bioinformatics, relentless pursuit for new drug, omics and clinical outcomes data, development of reliable in silico drug screening methods, novel validation approaches and strong international partnerships in personalized medicine we strive to find real working solutions to cure and prevent age-related diseases and aging itself. This mission will be achieved within within the regulatory frameworks as well as the legal and ethical boundaries and by working with the outstanding scientists, academic and medical institutions and pharmaceutical companies of impeccable credibility. Our goals are: to become the first and the largest drug discovery company in aging and age-related diseases; to become the first company to fully implement the concept of personalized science, where medicine is developed, tested and validated for individual patients in a safe high-throughput environment.
HQBaltimore, US

Latest Updates

Employees (est.) (Jan 2020)49(-5%)

Key People/Management at InSilico Medicine

Alex Zhavoronkov

Alex Zhavoronkov

Qingsong Zhu

Qingsong Zhu

Alex Aliper

Alex Aliper

President of EMEA
Ivan Ozerov

Ivan Ozerov

Director, Drug Discovery
Quentin Vanhaelen

Quentin Vanhaelen

Director, Virtual Human Project
Show more

InSilico Medicine Office Locations

InSilico Medicine has an office in Baltimore
Baltimore, US (HQ)
1101 E 33rd St
Show all (2)

InSilico Medicine Financials and Metrics

Summary Metrics

Founding Date


InSilico Medicine total Funding

$51.3 m

InSilico Medicine latest funding size

$37 m

Time since last funding

4 months ago

InSilico Medicine investors

InSilico Medicine's latest funding round in September 2019 was reported to be $37 m. In total, InSilico Medicine has raised $51.3 m
Show all financial metrics

InSilico Medicine Online and Social Media Presence

Embed Graph

InSilico Medicine News and Updates

Insilico Medicine and ChemDiv form a strategic drug discovery service alliance

SAN DIEGO, Oct. 16, 2019 /PRNewswire/ -- Insilico Medicine and ChemDiv, Inc. launched a new strategic collaboration to provide certain pharmaceutical and biotechnology companies with end-to-end drug discovery solutions. This collaboration combines the most advanced artificial intelligence...

CTFH and Insilico Medicine Enter Al Drug Discovery Collaboration Focused On Accelerating First-in-Class Therapeutics, Worth Up to $200 million

HONG KONG and NANJING, China, Oct. 9, 2019 /PRNewswire/ -- Insilico Medicine, a company developing an end-to-end drug discovery pipeline utilizing the latest advances in deep learning, has entered into a two-program AI drug discovery collaboration agreement with Jiangsu Chia Tai Fenghai...

InSilico Medicine Frequently Asked Questions

  • When was InSilico Medicine founded?

    InSilico Medicine was founded in 2014.

  • Who are InSilico Medicine key executives?

    InSilico Medicine's key executives are Alex Zhavoronkov, Qingsong Zhu and Alex Aliper.

  • How many employees does InSilico Medicine have?

    InSilico Medicine has 49 employees.

  • Who are InSilico Medicine competitors?

    Competitors of InSilico Medicine include Tempus, MedWhat and Sensely.

  • Where is InSilico Medicine headquarters?

    InSilico Medicine headquarters is located at 1101 E 33rd St, Baltimore.

  • Where are InSilico Medicine offices?

    InSilico Medicine has an office in Baltimore.

  • How many offices does InSilico Medicine have?

    InSilico Medicine has 2 offices.